Metabolite Biomarkers for Early AMD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Age-Related Macular Degeneration (AMD) are often asymptomatic in early stages and not reliably detectable until advanced, leading to delayed detection and progression to blinding forms of the disease, with a need for accessible and effective screening tools.
Innovation Solution
The use of mass spectrometry on bodily fluid samples to determine the levels of specific metabolites, such as 1-stearoyl-2-oleoyl-GPC, stearoyl-arachidonoyl-glycerol, and linoleoyl-arachidonoyl-glycerol, and applying principle component analysis to identify AMD presence and stage, followed by potential therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If routine eye exam is used to diagnose AMD, then the diagnostic method is simple and accessible, but the disease cannot be detected until advanced stages leading to visual symptoms
Solution Approach 1:
The patent applies preliminary action by measuring metabolite levels in bodily fluids (blood, urine, ocular fluids) to detect AMD before visual symptoms appear. The metabolite profile analysis serves as an early warning system that identifies the disease in pre-symptomatic stages, allowing intervention before irreversible damage occurs. This shifts detection from reactive (after symptoms) to proactive (before symptoms).
Solution Approach 2:
The patent uses metabolites in bodily fluids as intermediary biomarkers that reflect the pathological processes of AMD. These metabolite profiles serve as mediators between the actual retinal pathology and the diagnostic measurement, allowing indirect but early detection of disease processes before they manifest as visible ocular changes or symptoms.
2Measurement precision
If advanced diagnostic methods are used to detect AMD earlier, then detection accuracy improves, but the complexity and accessibility of the diagnostic tool decreases
Solution Approach 1:
The patent applies self-service by using naturally occurring metabolites in the patient's own bodily fluids as the diagnostic markers. The body itself produces the biomarkers through its metabolic processes in response to AMD pathology. This eliminates the need for external tracers, contrast agents, or complex test administrations, simplifying the diagnostic approach while maintaining high precision.
Solution Approach 2:
The metabolite profiling approach serves multiple functions: it detects AMD presence, stages disease severity, and potentially monitors treatment response. A single metabolic panel can address multiple diagnostic needs, reducing the requirement for multiple separate complex tests while providing comprehensive disease assessment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for early detection and staging of AMD, enabling timely intervention and potentially slowing disease progression, with a high sensitivity and selectivity in distinguishing AMD cases from controls and differentiating severity stages.
Implementation Method 1
performing mass spectrometry on a body fluid sample, such as blood, urine, or ocular fluid, to determine the amount of a set of metabolites in the sample
Data Source
AI summary
This disclosure relates to biomarkers for Age-Related Macular Degeneration (AMD) and methods of use thereof, e.g., methods of the use of biomarkers for determining that a subject has Age-related Macular Degeneration (AMD) or determining the stage of AMD in a subject.